Across TCGA pan-cancer cohorts, FBLL1 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of FBLL1’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where FBLL1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types FBLL1 is over-expressed in tumor, although a few such as PDAC and COAD show the opposite, repressed pattern.

CCRCC, PDAC, and COAD are the cancer types where FBLL1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FBLL1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	II,III,IV	+0.479	<.001	11	view →
PDAC	Male	All	−0.727	<.001	8	view →
COAD	All	All	−1.234	.020	6	view →
HNSC	Male	All	−0.839	.003	6	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: FBLL1 RNA expression & survival · all FBLL1 data types